Treatment in EGFR-mutated non-small cell lung cancer

How to block the receptor and overcome resistance mechanisms

Claudia Proto, Giuseppe Lo Russo, Giulia Corrao, Monica Ganzinelli, Francesco Facchinetti, Roberta Minari, Marcello Tiseo, Marina Chiara Garassino

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) have radically changed the therapeutic management strategies. Currently, erlotinib, gefitinib, and afatinib are all approved as standard first-line treatment in EGFR-mutated NSCLC. However, despite the proven efficacy, some EGFR-mutated NSCLCs do not respond to EGFR TKIs, while some patients, after a favorable and prolonged response to EGFR TKIs, inevitably progress within about 10-14 months. Epidermal growth factor receptor-dependent mechanisms, activation of alternative pathways, or phenotypic transformation can cause the resistance to EGFR TKIs. The exon 20 p.Thr790Met point mutation (T790M) is responsible for about 60% of cases of resistance when progression occurs. A third-generation TKI, osimertinib, improved outcome in patients harboring T790M after first- and second-generation TKI treatment. However, resistance develops even after treatment with third-generation drugs. To date, the Cys797Ser (C797S) mutation in exon 20 of EGFR is the most well-known resistance mutation after osimertinib. Fourth-generation TKIs are already under development. Nevertheless, additional information is needed to better understand and effectively overcome resistance. The aim of this review is to report recent advances and future perspectives in the treatment of EGFR-mutated NSCLC, highlighting the resistance mechanisms that underlie disease progression.

Original languageEnglish
Pages (from-to)325-337
Number of pages13
JournalTumori
Volume103
Issue number4
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Point Mutation
Mutation
Exons
Disease Progression

Keywords

  • Epidermal growth factor receptor
  • Non-small cell lung cancer
  • Resistance mechanisms
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment in EGFR-mutated non-small cell lung cancer : How to block the receptor and overcome resistance mechanisms. / Proto, Claudia; Lo Russo, Giuseppe; Corrao, Giulia; Ganzinelli, Monica; Facchinetti, Francesco; Minari, Roberta; Tiseo, Marcello; Garassino, Marina Chiara.

In: Tumori, Vol. 103, No. 4, 01.07.2017, p. 325-337.

Research output: Contribution to journalReview article

Proto, C, Lo Russo, G, Corrao, G, Ganzinelli, M, Facchinetti, F, Minari, R, Tiseo, M & Garassino, MC 2017, 'Treatment in EGFR-mutated non-small cell lung cancer: How to block the receptor and overcome resistance mechanisms', Tumori, vol. 103, no. 4, pp. 325-337. https://doi.org/10.5301/tj.5000663
Proto, Claudia ; Lo Russo, Giuseppe ; Corrao, Giulia ; Ganzinelli, Monica ; Facchinetti, Francesco ; Minari, Roberta ; Tiseo, Marcello ; Garassino, Marina Chiara. / Treatment in EGFR-mutated non-small cell lung cancer : How to block the receptor and overcome resistance mechanisms. In: Tumori. 2017 ; Vol. 103, No. 4. pp. 325-337.
@article{0fb93d1e764548d199bce66ef4d88de2,
title = "Treatment in EGFR-mutated non-small cell lung cancer: How to block the receptor and overcome resistance mechanisms",
abstract = "In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) have radically changed the therapeutic management strategies. Currently, erlotinib, gefitinib, and afatinib are all approved as standard first-line treatment in EGFR-mutated NSCLC. However, despite the proven efficacy, some EGFR-mutated NSCLCs do not respond to EGFR TKIs, while some patients, after a favorable and prolonged response to EGFR TKIs, inevitably progress within about 10-14 months. Epidermal growth factor receptor-dependent mechanisms, activation of alternative pathways, or phenotypic transformation can cause the resistance to EGFR TKIs. The exon 20 p.Thr790Met point mutation (T790M) is responsible for about 60{\%} of cases of resistance when progression occurs. A third-generation TKI, osimertinib, improved outcome in patients harboring T790M after first- and second-generation TKI treatment. However, resistance develops even after treatment with third-generation drugs. To date, the Cys797Ser (C797S) mutation in exon 20 of EGFR is the most well-known resistance mutation after osimertinib. Fourth-generation TKIs are already under development. Nevertheless, additional information is needed to better understand and effectively overcome resistance. The aim of this review is to report recent advances and future perspectives in the treatment of EGFR-mutated NSCLC, highlighting the resistance mechanisms that underlie disease progression.",
keywords = "Epidermal growth factor receptor, Non-small cell lung cancer, Resistance mechanisms, Tyrosine kinase inhibitors",
author = "Claudia Proto and {Lo Russo}, Giuseppe and Giulia Corrao and Monica Ganzinelli and Francesco Facchinetti and Roberta Minari and Marcello Tiseo and Garassino, {Marina Chiara}",
year = "2017",
month = "7",
day = "1",
doi = "10.5301/tj.5000663",
language = "English",
volume = "103",
pages = "325--337",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Treatment in EGFR-mutated non-small cell lung cancer

T2 - How to block the receptor and overcome resistance mechanisms

AU - Proto, Claudia

AU - Lo Russo, Giuseppe

AU - Corrao, Giulia

AU - Ganzinelli, Monica

AU - Facchinetti, Francesco

AU - Minari, Roberta

AU - Tiseo, Marcello

AU - Garassino, Marina Chiara

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) have radically changed the therapeutic management strategies. Currently, erlotinib, gefitinib, and afatinib are all approved as standard first-line treatment in EGFR-mutated NSCLC. However, despite the proven efficacy, some EGFR-mutated NSCLCs do not respond to EGFR TKIs, while some patients, after a favorable and prolonged response to EGFR TKIs, inevitably progress within about 10-14 months. Epidermal growth factor receptor-dependent mechanisms, activation of alternative pathways, or phenotypic transformation can cause the resistance to EGFR TKIs. The exon 20 p.Thr790Met point mutation (T790M) is responsible for about 60% of cases of resistance when progression occurs. A third-generation TKI, osimertinib, improved outcome in patients harboring T790M after first- and second-generation TKI treatment. However, resistance develops even after treatment with third-generation drugs. To date, the Cys797Ser (C797S) mutation in exon 20 of EGFR is the most well-known resistance mutation after osimertinib. Fourth-generation TKIs are already under development. Nevertheless, additional information is needed to better understand and effectively overcome resistance. The aim of this review is to report recent advances and future perspectives in the treatment of EGFR-mutated NSCLC, highlighting the resistance mechanisms that underlie disease progression.

AB - In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) have radically changed the therapeutic management strategies. Currently, erlotinib, gefitinib, and afatinib are all approved as standard first-line treatment in EGFR-mutated NSCLC. However, despite the proven efficacy, some EGFR-mutated NSCLCs do not respond to EGFR TKIs, while some patients, after a favorable and prolonged response to EGFR TKIs, inevitably progress within about 10-14 months. Epidermal growth factor receptor-dependent mechanisms, activation of alternative pathways, or phenotypic transformation can cause the resistance to EGFR TKIs. The exon 20 p.Thr790Met point mutation (T790M) is responsible for about 60% of cases of resistance when progression occurs. A third-generation TKI, osimertinib, improved outcome in patients harboring T790M after first- and second-generation TKI treatment. However, resistance develops even after treatment with third-generation drugs. To date, the Cys797Ser (C797S) mutation in exon 20 of EGFR is the most well-known resistance mutation after osimertinib. Fourth-generation TKIs are already under development. Nevertheless, additional information is needed to better understand and effectively overcome resistance. The aim of this review is to report recent advances and future perspectives in the treatment of EGFR-mutated NSCLC, highlighting the resistance mechanisms that underlie disease progression.

KW - Epidermal growth factor receptor

KW - Non-small cell lung cancer

KW - Resistance mechanisms

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85027506932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027506932&partnerID=8YFLogxK

U2 - 10.5301/tj.5000663

DO - 10.5301/tj.5000663

M3 - Review article

VL - 103

SP - 325

EP - 337

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -